APGE Apogee Therapeutics
Price Chart
Executive Summary
Apogee Therapeutics announced positive 16-week Phase 2 APEX Part B data for zumilokibart in moderate-to-severe atopic dermatitis, meeting primary and secondary endpoints with high statistical significance. The mid-dose achieved 65.9% EASI-75 (41.9% placebo-adjusted) and a favorable safety profile, supporting advancement into Phase 3 trials in 2H 2026. A strategic financing collaboration with Blackstone Life Sciences was also announced, expected to fund through commercialization.
Actionable Insight
The robust Phase 2 data and Blackstone financing significantly de-risk zumilokibart's path to market. Traders should watch for regulatory interactions and Phase 3 initiation in 2H 2026. The pipeline-in-a-product potential (asthma, EoE) adds upside optionality. Monitor upcoming 52-week Part B data and any partnership/out-licensing news.
Key Facts
- Phase 2 APEX Part B met primary endpoint: mid-dose zumilokibart achieved 65.9% EASI-75 vs 23.4% placebo (p<0.001).
- Key secondary endpoints met: IGA 0/1 46.0% vs 10.9%, EASI-90 47.4% vs 9.3%, I-NRS ≥4 50.5% vs 13.9% (all p<0.001).
- Very Low Disease Activity (vLDA) achieved in 20.6% of mid-dose patients vs 4.5% placebo (p<0.01).
- Safety profile consistent with class; conjunctivitis rate for mid-dose was 10.6% vs 20.7% for high dose.
- Company plans to initiate Phase 3 ADventure trials in AD in 2H 2026, Phase 2b ASPIRE in asthma in 1H 2027, and Phase 2a ELEVATE in EoE in 2H 2026.
- Strategic financing collaboration with Blackstone Life Sciences announced to fund through commercialization.
- Mid-dose selected for Phase 3 based on best clinical activity and tolerability.
Financial Impact
Not disclosed; financing collaboration with Blackstone Life Sciences expected to fund through commercialization of zumilokibart in AD, asthma, and EoE.
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 efficacy or safety results.
- Regulatory interactions could delay or alter Phase 3 trial design.
- Competition from existing IL-13/IL-4Rα biologics (e.g., dupilumab) and emerging therapies.
- Dependence on Blackstone financing terms and potential dilution if additional capital needed.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301719 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
13d ago
|
8-K
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 27, 2026
13d ago
|
8-K
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 27, 2026
13d ago
|
Press Release
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 27, 2026
13d ago
|
Press Release
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 26, 2026
14d ago
|
Press Release
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 16, 2026
25d ago
|
Insider Cluster
| $78.75 $82.81 | ▲ +5.16% | ▲ +3.54% | $83.01 (+5.41%) |
|
May 13, 2026
27d ago
|
144
| $83.94 $81.39 | ▼ −3.04% | ▼ −2.90% | $83.01 (−1.11%) |
|
May 11, 2026
29d ago
|
8-K
| $84.60 $78.75 | ▼ −6.91% | ▼ −6.83% | $83.01 (−1.88%) |
|
May 11, 2026
29d ago
|
Press Release
| $84.60 $78.75 | ▼ −6.91% | ▼ −6.83% | $83.01 (−1.88%) |
|
May 1, 2026
5w ago
|
Insider Cluster
| $80.75 $83.03 | ▲ +2.82% | ▲ +0.48% | $83.01 (+2.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access